Goldman Sachs Group Inc Amylyx Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,613,863 shares of AMLX stock, worth $8.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,613,863

Previous 2,610,420 38.18%

Holding current value

$8.54 Million

Previous $4.96 Million 5.42%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.65 - $3.24 $1.64 Million - $3.23 Million	-996,557 Reduced 38.18%	1,613,863 $5.23 Million
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.71 $539,080 - $901,795	-332,766 Reduced 11.31%	2,610,420 $4.96 Million
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $4.57 Million - $33 Million	1,686,325 Added 134.17%	2,943,186 $8.36 Million
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $841,677 - $1.29 Million	69,733 Added 5.87%	1,256,861 $18.5 Million
Q3 2023 May 14, 2024	SELL	$18.08 - $23.45 $1.26 Million - $1.64 Million	-69,733 Reduced 5.55%	1,187,128 $21.7 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $2.95 Million - $3.83 Million	-163,350 Reduced 12.1%	1,187,128 $21.7 Million
Q2 2023 May 14, 2024	SELL	$20.98 - $31.42 $329,260 - $493,105	-15,694 Reduced 1.15%	1,350,478 $29.1 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $329,260 - $493,105	-15,694 Reduced 1.15%	1,350,478 $29.1 Million
Q1 2023 May 14, 2024	BUY	$27.71 - $40.93 $9.14 Million - $13.5 Million	329,902 Added 31.84%	1,366,172 $40.1 Million
Q1 2023 May 11, 2023	BUY	$27.71 - $40.93 $9.14 Million - $13.5 Million	329,902 Added 31.84%	1,366,172 $40.1 Million
Q4 2022 May 14, 2024	BUY	$29.75 - $39.26 $19.5 Million - $25.8 Million	656,871 Added 173.13%	1,036,270 $38.3 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $19.5 Million - $25.8 Million	656,871 Added 173.13%	1,036,270 $38.3 Million
Q3 2022 May 14, 2024	SELL	$17.15 - $30.92 $15 Million - $27.1 Million	-877,462 Reduced 69.81%	379,399 $10.7 Million
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $6.51 Million - $11.7 Million	379,399 New	379,399 $0

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Amylyx Pharmaceuticals, Inc. Transaction History